skip to Main Content

Resistance to Immune Checkpoint Inhibition in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of only 5% to 7%, and immunotherapeutic approaches that have shown significant promise in other hard-to-treat tumors like melanoma have so far barely made a dent in survival for PDAC.

This is widely believed to be due to immunosuppression within the PDAC tumor microenvironment, which is the subject of 2 research presentations from the 34th Annual Meeting & Preconference Programs of the Society for Immunotherapy of Cancer, or SITC 2019, Read more . . . 

Back To Top